EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD33 expression combined with D15-MRD positivity identifies poor prognosis in children with ETV6::RUNX1-positive ALL

Xueling Zheng, Yuxi Luo, Ruidong Zhang, Xiaohang Liu, Pengli Huang, Chao Gao, Hui Chen, Jia Fan, Wei Lin, Jiaole Yu, Yuanyuan Zhang, Peijing Qi und 6 weitere

Annals of Hematology · 29.05.2026 · 105 (8)

DOI: 10.1007/s00277-026-07089-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 29.05.2026. Verfasst von Xueling Zheng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Center, National Key Discipline of Pediatric Hematology, Key Laboratory of Major Diseases in Children, Beijing Children's Hospital, Nation…. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sialic Acid Binding Ig-like Lectin 3, Oncogene Proteins, Fusion. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special "Yang Fan" Grant, Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special “Yang Fan” Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While ETV6 :: RUNX1 -positive acute lymphoblastic leukemia (ALL) is generally associated with favorable outcomes, a subset of patients experience relapse despite receiving standard therapy, underscoring the need for early biomarkers to identify high-risk subgroups. In this retrospective study of 345 consecutive pediatric patients with ETV6 :: RUNX1 -positive ALL treated in accordance with the protocol of the Chinese Children’s Leukemia Group (CCLG-ALL 2008), CD33 expression (CD33 + ) on leukemic blasts was detected in 55.9% of patients and was significantly associated with minimal residual disease (MRD) positivity on day 15 (D15-MRD-positive) (65.2% vs. 42.0%, P < 0.001). Multivariate analysis revealed CD33 + status as an independent risk factor for D15-MRD positivity (odds ratio (OR) = 2.66, 95% confidence interval (CI) 1.66–4.26). Among CD33 + patients, those who were D15-MRD-positive had significantly inferior 5-year and 10-year event-free survival (EFS) relative to those who were D15-MRD-negative (5-year EFS: 91.9% ± 2.4% vs. 100%, P = 0.027; 10-year EFS: 89.2% ± 3.0% vs. 100%, P = 0.014). This prognostic association was not observed in CD33-negative patients. In conclusion, the combination of CD33 + and D15-MRD-positivity may identify a distinct high-risk subgroup within ETV6 :: RUNX1 -positive ALL. Early intervention, potentially including CD33-directed therapy, may represent a promising strategy to improve outcomes in this subgroup, although further validation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitPrecursor Cell Lymphoblastic Leukemia-LymphomaSialic Acid Binding Ig-like Lectin 3Oncogene Proteins, FusionRepressor ProteinsProto-Oncogene Proteins c-etsHumansETS Translocation Variant 6 ProteinFemaleChildChild, PreschoolMaleNeoplasm, ResidualRetrospective StudiesPrognosisAdolescentInfantDisease-Free SurvivalBiomarkers, Tumor

Stichwörter der Autor:innen

ETV6:: RUNX1Acute lymphoblastic leukemiaCD33PediatricPrognosis

Substanzen

Core Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinSialic Acid Binding Ig-like Lectin 3CD33 protein, humanOncogene Proteins, FusionRUNX1 protein, humanRepressor ProteinsProto-Oncogene Proteins c-etsBiomarkers, Tumor

Autor:innen und Institutionen

  • Hematology Center, National Key Discipline of Pediatric Hematology, Key Laboratory of Major Diseases in Children, Beijing Children's Hospital, National Key Discipline of Pediatrics (Capital Medical University), Ministry…
  • Center for Clinical Epidemiology and Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
  • Department of Clinical Laboratory Center, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Minis…

Förderung

  • Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special "Yang Fan" Grant
  • Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special “Yang Fan” Grant

Zitieren

APA

Zheng, X., Luo, Y., Zhang, R., Liu, X., Huang, P., Gao, C., Chen, H., Fan, J., Lin, W., Yu, J., Zhang, Y., Qi, P., Wu, Y., Zhao, X., Li, J., Peng, X., Wang, T., & Zheng, H. (2026). CD33 expression combined with D15-MRD positivity identifies poor prognosis in children with ETV6::RUNX1-positive ALL. Annals of Hematology, 105(8). https://doi.org/10.1007/s00277-026-07089-8

Vancouver

Zheng X, Luo Y, Zhang R, Liu X, Huang P, Gao C, et al. CD33 expression combined with D15-MRD positivity identifies poor prognosis in children with ETV6::RUNX1-positive ALL. Annals of Hematology. 2026;105(8). doi:10.1007/s00277-026-07089-8

BibTeX
@article{Zheng2026,
  author = {Zheng, Xueling and Luo, Yuxi and Zhang, Ruidong and Liu, Xiaohang and Huang, Pengli and Gao, Chao and Chen, Hui and Fan, Jia and Lin, Wei and Yu, Jiaole and Zhang, Yuanyuan and Qi, Peijing and Wu, Ying and Zhao, Xiaoxi and Li, Jun and Peng, Xiaoxia and Wang, Tianyou and Zheng, Huyong},
  title = {CD33 expression combined with D15-MRD positivity identifies poor prognosis in children with ETV6::RUNX1-positive ALL},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {8},
  doi = {10.1007/s00277-026-07089-8}
}
Kostenlos starten →